Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within-study comparator cohort of mosunetuzumab IV in a similar patient population (N = 90; median follow-up: 22.5 months). The co-primary PK endpoints (C<sub>trough</sub> and AUC) were met, demonstrating non-inferior exposure of mosunetuzumab SC versus IV (observed C<sub>trough[C3]</sub>: geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20-1.61]; AUC<sub>0-84</sub>: GMR 1.06 [90% CI: 0.92-1.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7-84.7); complete response rate, 61.7% (95% CI: 51.1-71.5); median duration of complete response, 34.6 months (95% CI: 20.7-not evaluable [NE]); and median progression-free survival, 23.7 months (95% CI: 14.6-NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade ≥ 2: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed-duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety. Trial Registration: www.clinicaltrials.gov: NCT02500407.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2026-03-20
DOI
https://doi.org/10.1002/ajh.70225
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

Eva Cybulski, Vanda Teodoro, Denison Kuruvilla, Samuel Tracy et al.
American Journal of Hematology
Lymphoma Diagnosis and Treatment
article

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

Eva Cybulski, Vanda Teodoro, Denison Kuruvilla, Samuel Tracy, Volker Wiebking, Elicia Penuel, Sung‐Soo Yoon, Fidelis Sabalvaro, N Martín Gutiérrez, Michael C. Wei, Sarit Assouline, L. Elizabeth Budde, Pratyush Giri, Nancy L. Bartlett, Georg Hess, John Kuruvilla, Keith Fay, Joseph Chen, Stephen J. Schuster, Laurie H. Sehn, Martin Dreyling
article en

Abstract

Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed. We report the primary analysis of pharmacokinetics (PK), efficacy, and safety of mosunetuzumab SC (N = 94; median follow-up: 26.1 months) at the recommended Phase 2 dose (Cycle [C]1 Day [D]1: 5 mg; C1D8 and D15, and C2D1 onwards: 45 mg) in patients with R/R FL after ≥ 2 prior therapies, alongside data from a within-study comparator cohort of mosunetuzumab IV in a similar patient population (N = 90; median follow-up: 22.5 months). The co-primary PK endpoints (C<sub>trough</sub> and AUC) were met, demonstrating non-inferior exposure of mosunetuzumab SC versus IV (observed C<sub>trough[C3]</sub>: geometric mean ratio [GMR] 1.39 [90% confidence interval (CI): 1.20-1.61]; AUC<sub>0-84</sub>: GMR 1.06 [90% CI: 0.92-1.21]). Mosunetuzumab SC efficacy was consistent with IV: overall response rate, 76.6% (95% CI: 66.7-84.7); complete response rate, 61.7% (95% CI: 51.1-71.5); median duration of complete response, 34.6 months (95% CI: 20.7-not evaluable [NE]); and median progression-free survival, 23.7 months (95% CI: 14.6-NE). Mosunetuzumab SC demonstrated a favorable safety profile versus mosunetuzumab IV with a numerically lower rate (29.8% vs. 44.4%) and severity (grade ≥ 2: 9.6% vs. 18.9%) of cytokine release syndrome (CRS) events. Mosunetuzumab SC combines the benefits of short administration time, fixed-duration treatment, outpatient accessibility, and low CRS rate, offering clinically meaningful improvements in patient convenience and safety. Trial Registration: www.clinicaltrials.gov: NCT02500407.

American Journal of Hematology
Roche (Switzerland) (CH), BC Cancer Agency (CA), City Of Hope National Medical Center (US), Royal Adelaide Hospital (AU), Johannes Gutenberg University Mainz (DE), Washington University in St. Louis (US), Royal North Shore Hospital (AU), Jewish General Hospital (CA), Spinal Cord Injury BC (CA), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), St Vincent's Hospital Melbourne (AU), University Medical Center of the Johannes Gutenberg University Mainz (DE), Centro de Investigación del Cáncer (ES), University of Pennsylvania (US), Ludwig-Maximilians-Universität München (DE)
Good health and well-being
Openalex Percentile: Top 15%
Lymphoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.